Executive Summary
Overnight SEC filings reveal a mixed but cautious tone ahead of today's open, with a notable cluster of insider selling at high materiality levels. SharkNinja's CEO sold $38.8M in stock under a 10b5-1 plan, while Madrigal Pharmaceuticals' CEO exercised and sold options worth $372K, both generating bearish signals.
The most critical development is an activist filing at Phunware, where Goldenwise Capital disclosed a 6.9% stake, publicly criticized governance, and threatened a proxy contest—the highest materiality event of the session. In the financial sector, Northfield Bancorp saw a wave of insider dispositions to the issuer, including the CEO returning 464K shares, suggesting a capital return event. On the positive side, Fulcrum Therapeutics saw a 10% owner buy $594K worth of stock, a bullish insider signal. Period-over-period data was limited in these filings, but the concentration of insider selling in biotech and consumer goods, combined with activist pressure at Phunware and a dilutive financing at VisionWave, points to a cautious market tone with select activist and insider-buying opportunities.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13D · 8-K
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from July 20, 2026.
Investment Signals (10)
- SharkNinja ↓ (BEARISH)▲
CEO Barrocas sold 250,000 shares at $155.01 for $38.8M under a 10b5-1 plan, reducing his stake by 11.1%. While pre-planned, the sheer size signals potential peak valuation concerns
- Madrigal Pharmaceuticals ↓ (BEARISH)▲
CEO Sibold exercised 50,000 options and sold a portion for $372K across 12 transactions. The exercise-and-sell pattern at ~$543 suggests management is locking in gains near recent highs
- Fulcrum Therapeutics ↓ (BULLISH)▲
10% owner Tang Kevin bought 167,616 shares at ~$3.54 for $594K, increasing his stake by 2.4%. Insider buying in a beaten-down biotech signals confidence in pipeline value
-
Goldenwise Capital disclosed a 6.9% stake, publicly criticized the board, and proposed four director candidates. The fund holds short put/call options at $2.50 expiring July 2026, creating a catalyst for a proxy fight [BULLISH for activism]
- Accelerant Holdings ↓ (BEARISH)▲
CEO Radke sold 94,777 shares at ~$13.60 for $1.29M under a 10b5-1 plan. The sale represents 0.3% of his stake, but the insider selling pattern in a recent IPO is a cautionary signal
- Nerdy Inc. ↓ (BEARISH)▲
Four officers (CAO, CLO, CFO, COO) collectively sold 103,544 shares at $0.83 for $85.9K. Broad-based insider selling at near-all-time-low prices suggests lack of confidence in near-term turnaround
- Mineralys Therapeutics ↓ (BEARISH)▲
CMO Rodman exercised 416 options at $15.44 and immediately sold at $26.53 for a 72% gain. The same-day exercise-and-sell pattern is a bearish signal from a key executive
- Northfield Bancorp ↓ (BULLISH)▲
Chairman/CEO Klein disposed of 464,261 shares to the issuer, and 10 other insiders collectively disposed of ~1.1M shares. This pattern is consistent with a share repurchase or capital return event, which is positive for remaining shareholders
- Gran Tierra Energy ↓ (NEUTRAL)▲
Four executives (COO, CEO, EVPs) were awarded small stock grants totaling ~$12.3K at $6.48. These routine equity grants align management with shareholders but are not material
- SYNAPTICS ↓ (BEARISH)▲
Four executives had shares withheld for taxes totaling ~$2.9M at $114.05, with two also selling small amounts. The tax-withholding pattern is routine, but the additional sales by Bodensteiner and Patel add a mildly bearish tint
Risk Flags (10)
- SharkNinja/CEO Mega-Sale↓ [HIGH RISK]▼
CEO Barrocas sold $38.8M in a single day, the largest insider sale in this batch. Even under a 10b5-1 plan, the magnitude (11% of stake) raises questions about growth sustainability at current valuation
- Nerdy Inc./Broad Insider Exodus↓ [HIGH RISK]▼
Four C-suite officers sold stock simultaneously at $0.83, near the 52-week low. The coordinated selling by CAO, CLO, CFO, and COO signals deep internal pessimism about the business trajectory
- Phunware/Governance Crisis↓ [HIGH RISK]▼
Goldenwise Capital's public criticism of the board, including no response to 10+ emails, and the threat of a proxy contest creates significant uncertainty. The fund's short option positions at $2.50 add a complex layer of potential conflict
- VisionWave Holdings/Dilutive Financing↓ [HIGH RISK]▼
The company issued $15M in convertible debentures at an 85% discount to principal, with warrants for 1.8M shares. This is highly dilutive to existing shareholders and signals cash burn
- Accelerant Holdings/Insider Selling Post-IPO↓ [MEDIUM RISK]▼
CEO Radke's $1.29M sale under a 10b5-1 plan, combined with the stock trading at $13.51, suggests insiders are taking profits early in the public life, a red flag for growth expectations
- Madrigal Pharmaceuticals/CEO Cash-Out↓ [MEDIUM RISK]▼
CEO Sibold's exercise-and-sell of 50,000 options at ~$543, netting ~$372K, comes after a significant run-up. The pattern of selling after exercise is a classic insider de-risking signal
- Gloo Holdings/10% Owner Dumping↓ [MEDIUM RISK]▼
Thrivent Financial sold 17,000 shares at $3.26-$3.44 for $56.8K, reducing its stake. A large institutional holder selling at low prices is a negative signal
- Petrobras/BNDESPAR Stake Reduction↓ [MEDIUM RISK]▼
BNDESPAR sold 50.96M preferred shares in open market, reducing its stake to 15.9%. State-linked entity selling is a macro negative for Brazilian equities
- SYNAPTics/Multiple Insider Sales↓ [LOW-MEDIUM RISK]▼
Three executives (Bodensteiner, Patel, Gupta) sold shares in addition to tax-withholding transactions. While small in value, the pattern of voluntary selling across multiple officers is a cautionary signal
- Q32 Bio/OrbiMed Lock-Up Expiration↓ [MEDIUM RISK]▼
OrbiMed's 13.9% stake is subject to a lock-up expiring ~45 trading days from July 15, 2026 (approx. mid-September). The potential for a large sell-off post-lock-up is a medium-term risk
Opportunities (9)
- Phunware/Activist Catalyst↓ (OPPORTUNITY)◆
Goldenwise Capital's 6.9% stake and proxy fight threat could unlock value. The fund's proposed directors and criticism of capital allocation suggest a turnaround play. Monitor for further 13D filings and proxy materials
- Fulcrum Therapeutics/Insider Buying Signal↓ (OPPORTUNITY)◆
10% owner Tang Kevin bought $594K worth of stock at ~$3.54, increasing his stake. Insider buying in a small-cap biotech often precedes positive clinical or regulatory news
- Northfield Bancorp/Capital Return Event↓ (OPPORTUNITY)◆
The mass disposition of shares to the issuer by 11 insiders (including CEO's 464K shares) strongly suggests a tender offer or special dividend. If confirmed, this could be a 10-15% upside catalyst
- Mineralys Therapeutics/Insider Exercise Arbitrage↓ (OPPORTUNITY)◆
CMO Rodman exercised options at $15.44 and sold at $26.53, a 72% gain. While the sale is bearish, the exercise signals that management sees value above $26.53. The stock's current price near $26.53 could be a support level
- Gran Tierra Energy/Management Alignment↓ (OPPORTUNITY)◆
Four executives were awarded stock at $6.48, increasing their skin in the game. While small, the consistent insider buying via grants at current levels suggests management sees value
- Studio City International/Debt Redemption↓ (OPPORTUNITY)◆
The company completed a partial redemption of its 6.5% senior notes due 2028. Deleveraging via debt reduction is credit-positive and could lead to equity value creation if the trend continues
- America Movil/Peru Fiber Acquisition↓ (OPPORTUNITY)◆
The acquisition of WOW Tel in Peru expands fiber-optic footprint outside Lima. This is a bolt-on acquisition that could drive revenue synergies in an underserved market
- Select Water Solutions/CEO Mega-Grant↓ (OPPORTUNITY)◆
CEO Schmitz was awarded 250,000 shares and 250,000 performance units. The massive equity grant (doubling his holdings) strongly aligns management with long-term performance
- Q32 Bio/Equity Grants to Leadership↓ (OPPORTUNITY)◆
CEO Morrison was awarded 132,000 shares, CFO Kalowski 53,250, and CSO Violette 37,500. These grants signal board confidence in the pipeline and management team
Sector Themes (5)
- Biotech Insider Selling Wave◆
Madrigal, Mineralys, and SYNAPTics all saw insider sales, with Madrigal's CEO leading at $372K. The pattern of exercise-and-sell suggests biotech executives are taking profits after recent rallies, a cautious signal for the sector
- Consumer Goods Insider Profit-Taking◆
SharkNinja's CEO sold $38.8M and Accelerant's CEO sold $1.29M, both under 10b5-1 plans. Consumer goods insiders are locking in gains, potentially signaling peak demand or valuation concerns
- Financial Sector Capital Return Activity◆
Northfield Bancorp's mass insider dispositions to the issuer (11 insiders, ~1.6M shares) point to a potential tender offer or special dividend. This could be a theme across small-cap banks with excess capital
- Activist Activity in Small-Cap Tech◆
Phunware's activist filing by Goldenwise Capital is the highest-materiality event. Small-cap tech with cash burn and governance issues is attracting activist attention, creating both risk and opportunity
- Foreign Issuer Routine Filings Dominate◆
7 of 50 filings were routine 6-Ks from foreign issuers (Gerdau, ING, UMC, Alterity, Studio City, America Movil, Innate Pharma). These are low-materiality but indicate ongoing cross-border M&A and debt management activity
Watch List (8)
- Phunware/Proxy Contest↓ (IMMINENT)👁
Goldenwise Capital has proposed four directors and may launch a proxy fight. Watch for Schedule 14A filings and shareholder response. The short put/call options at $2.50 expiring July 2026 add near-term pressure
- Northfield Bancorp/Capital Return↓ (SHORT-TERM)👁
The mass insider dispositions suggest a tender offer or special dividend announcement. Watch for 8-K filings detailing the capital return plan. If confirmed, could be a 10-15% upside catalyst
- VisionWave Holdings/Stockholder Vote↓ (MEDIUM-TERM)👁
The company needs stockholder approval to issue shares above the Nasdaq exchange cap of 5.5M. Watch for proxy materials and vote outcome. Failure could limit financing flexibility
- Q32 Bio/Lock-Up Expiration↓ (MEDIUM-TERM)👁
OrbiMed's 13.9% stake is locked up until ~mid-September 2026. Watch for insider selling post-lock-up, which could pressure the stock
- Fulcrum Therapeutics/Clinical Catalyst↓ (MEDIUM-TERM)👁
10% owner Tang Kevin's $594K insider buy may precede positive clinical or regulatory news. Watch for trial data releases or FDA updates
- 👁
CEO Sibold's exercise-and-sell pattern may continue. Watch for further Form 4 filings. If selling accelerates, it could signal peak valuation
- America Movil/WOW Tel Acquisition Closing↓ (MEDIUM-TERM)👁
The deal is subject to INDECOPI approval in Peru. Watch for regulatory clearance announcements, which could be a catalyst for AMX shares
- Alterity Therapeutics/BTIG Conference↓ (IMMINENT)👁
The company is presenting at the BTIG Biotechnology Conference. Watch for presentation materials and potential partnership or data announcements
Filing Analyses
(50)
20-07-2026
Chief Operating Officer Morin Sebastien was awarded 687 Common Stock at $6.48 (~$4.45K). Morin Sebastien holds 37,067 shares after the transaction.
- · Chief Operating Officer Morin Sebastien was awarded 687 Common Stock at $6.48 (~$4.45K)
20-07-2026
President and CEO Guidry Gary was awarded 641 Common Stock at $6.48 (~$4.15K). Guidry Gary holds 507,546 shares after the transaction.
- · President and CEO Guidry Gary was awarded 641 Common Stock at $6.48 (~$4.15K)
20-07-2026
See Remarks Ganesan Satish had withheld for taxes 1,465 Common Stock at $114.05 (~$167K). Ganesan Satish holds 61,834 shares after the transaction.
- · See Remarks Ganesan Satish had withheld for taxes 1,465 Common Stock at $114.05 (~$167K)
20-07-2026
EVP, Corporate Services Evans Jim was awarded 206 Common Stock at $6.48 (~$1.33K). Evans Jim holds 49,752 shares after the transaction.
- · EVP, Corporate Services Evans Jim was awarded 206 Common Stock at $6.48 (~$1.33K)
20-07-2026
EVP, Legal and Land Abraham Phillip D was awarded 367 Common Stock at $6.48 (~$2.38K). Abraham Phillip D holds 43,888 shares after the transaction.
- · EVP, Legal and Land Abraham Phillip D was awarded 367 Common Stock at $6.48 (~$2.38K)
20-07-2026
See Remarks Rizvi Ken had withheld for taxes 1,473 Common Stock at $114.05 (~$168K). Rizvi Ken holds 104,417 shares after the transaction.
- · See Remarks Rizvi Ken had withheld for taxes 1,473 Common Stock at $114.05 (~$168K)
20-07-2026
Co-Founder, CEO RADKE JEFFREY L sold 80,000 Class A Common Shares at $13.51 (~$1.08M). RADKE JEFFREY L holds 27,847,162 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Co-Founder, CEO RADKE JEFFREY L sold 14,777 Class A Common Shares at $14.30 (~$211K)
- · Co-Founder, CEO RADKE JEFFREY L sold 80,000 Class A Common Shares at $13.51 (~$1.08M)
20-07-2026
See Remarks Bodensteiner Lisa had withheld for taxes 1,052 Common Stock at $114.05 (~$120K). Bodensteiner Lisa holds 60,487 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See Remarks Bodensteiner Lisa had withheld for taxes 1,052 Common Stock at $114.05 (~$120K)
- · See Remarks Bodensteiner Lisa sold 284 Common Stock at $114.62 (~$32.6K)
- · See Remarks Bodensteiner Lisa sold 166 Common Stock at $115.56 (~$19.2K)
20-07-2026
10% owner THRIVENT FINANCIAL FOR LUTHERANS sold 7,000 Class A Common Stock at $3.44 (~$24.1K). THRIVENT FINANCIAL FOR LUTHERANS holds 4,253,000 shares after the transaction.
- · 10% owner THRIVENT FINANCIAL FOR LUTHERANS sold 5,000 Class A Common Stock at $3.26 (~$16.3K)
- · 10% owner THRIVENT FINANCIAL FOR LUTHERANS sold 5,000 Class A Common Stock at $3.28 (~$16.4K)
- · 10% owner THRIVENT FINANCIAL FOR LUTHERANS sold 7,000 Class A Common Stock at $3.44 (~$24.1K)
20-07-2026
Chief Accounting Officer Callaway Kyle sold 13,377 Class A Common Stock at $0.83 (~$11.1K). Callaway Kyle holds 487,120 shares after the transaction.
- · Chief Accounting Officer Callaway Kyle sold 13,377 Class A Common Stock at $0.83 (~$11.1K)
20-07-2026
Chief Legal Officer Swenson Christopher C. sold 22,707 Class A Common Stock at $0.83 (~$18.8K). Swenson Christopher C. holds 2,468,924 shares after the transaction.
- · Chief Legal Officer Swenson Christopher C. sold 22,707 Class A Common Stock at $0.83 (~$18.8K)
20-07-2026
President & CEO Schmitz John was awarded 250,000 Class A Common Stock. 10 transactions reported in total. Schmitz John holds 536,436 shares after the transaction.
- · President & CEO Schmitz John was awarded 250,000 Class A Common Stock
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
- · President & CEO Schmitz John was awarded 125,000 Performance Share Units
20-07-2026
See remarks below Patel Rahul G. had withheld for taxes 19,898 Common Stock at $114.05 (~$2.27M). 4 transactions reported in total. Patel Rahul G. holds 86,868 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See remarks below Patel Rahul G. had withheld for taxes 19,898 Common Stock at $114.05 (~$2.27M)
- · See remarks below Patel Rahul G. sold 1,568 Common Stock at $114.15 (~$179K)
- · See remarks below Patel Rahul G. sold 2,486 Common Stock at $115.11 (~$286K)
- · See remarks below Patel Rahul G. sold 500 Common Stock at $115.79 (~$57.9K)
20-07-2026
Executive VP and CFO Corkrean John J was awarded 221.27 Phantom Units at $56.96 (~$12.6K).
- · Executive VP and CFO Corkrean John J was awarded 221.27 Phantom Units at $56.96 (~$12.6K)
20-07-2026
Sr. VP, International Growth Campe Heather was awarded 39.11 Phantom Units at $56.96 (~$2.23K).
- · Sr. VP, International Growth Campe Heather was awarded 39.11 Phantom Units at $56.96 (~$2.23K)
20-07-2026
Chief Medical Officer Rodman David Malcom sold 416 Common Stock at $26.53 (~$11K). Rodman David Malcom holds 51,384 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Medical Officer Rodman David Malcom exercised/converted 416 Common Stock at $15.44 (~$6.42K)
- · Chief Medical Officer Rodman David Malcom sold 416 Common Stock at $26.53 (~$11K)
- · Chief Medical Officer Rodman David Malcom exercised/converted 416 Stock Option
20-07-2026
President and CEO Sibold William John sold 680 Common Stock at $547.70 (~$372K). 12 transactions reported in total. Sibold William John holds 209,329 shares after the transaction.
- · President and CEO Sibold William John exercised/converted 50,000 Common Stock
- · President and CEO Sibold William John sold 140 Common Stock at $542.75 (~$76K)
- · President and CEO Sibold William John sold 110 Common Stock at $543.79 (~$59.8K)
- · President and CEO Sibold William John sold 545 Common Stock at $544.71 (~$297K)
- · President and CEO Sibold William John sold 275 Common Stock at $545.71 (~$150K)
- · President and CEO Sibold William John sold 269 Common Stock at $547.08 (~$147K)
- · President and CEO Sibold William John sold 680 Common Stock at $547.70 (~$372K)
- · President and CEO Sibold William John sold 47 Common Stock at $548.87 (~$25.8K)
20-07-2026
Chief Financial Officer Bagga Atul Madan Mohan sold 36,426 Class A Common Stock at $0.83 (~$30.2K). Bagga Atul Madan Mohan holds 1,463,574 shares after the transaction.
- · Chief Financial Officer Bagga Atul Madan Mohan sold 36,426 Class A Common Stock at $0.83 (~$30.2K)
20-07-2026
10% owner TANG KEVIN bought 116,671 Common Stock at $3.56 (~$415K). TANG KEVIN holds 7,080,945 shares after the transaction.
- · 10% owner TANG KEVIN bought 116,671 Common Stock at $3.56 (~$415K)
- · 10% owner TANG KEVIN bought 50,945 Common Stock at $3.52 (~$179K)
20-07-2026
Chief Operating Officer Paszterko John Andrew sold 31,034 Class A Common Stock at $0.83 (~$25.8K). Paszterko John Andrew holds 1,718,721 shares after the transaction.
- · Chief Operating Officer Paszterko John Andrew sold 31,034 Class A Common Stock at $0.83 (~$25.8K)
20-07-2026
Chief Executive Officer Barrocas Mark sold 250,000 Ordinary Shares at $155.01 (~$38.8M). Barrocas Mark holds 1,996,659 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Executive Officer Barrocas Mark sold 250,000 Ordinary Shares at $155.01 (~$38.8M)
20-07-2026
CEO Morrison Jodie Pope was awarded 132,000 Common Stock. Morrison Jodie Pope holds 353,104 shares after the transaction.
- · CEO Morrison Jodie Pope was awarded 132,000 Common Stock
20-07-2026
CFO and President Kalowski Lee was awarded 53,250 Common Stock. Kalowski Lee holds 142,443 shares after the transaction.
- · CFO and President Kalowski Lee was awarded 53,250 Common Stock
20-07-2026
See Remarks Gupta Vikram had withheld for taxes 1,488 Common Stock at $114.05 (~$170K). Gupta Vikram holds 81,586 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See Remarks Gupta Vikram had withheld for taxes 1,488 Common Stock at $114.05 (~$170K)
- · See Remarks Gupta Vikram sold 350 Common Stock at $114.76 (~$40.2K)
- · See Remarks Gupta Vikram sold 10 Common Stock at $115.54 (~$1.16K)
20-07-2026
OrbiMed Advisors LLC and related entities filed Amendment No. 4 to Schedule 13D, reporting that their aggregate beneficial ownership in Q32 Bio Inc. decreased from over 15% to 13.9% due to an increase in the company's outstanding shares. The filing discloses that OrbiMed Private Investments VII, LP holds 3,502,987 shares (11.8%) and OrbiMed Genesis Master Fund, L.P. holds 625,000 shares (2.1%), with a lock-up agreement restricting sales for 45 trading days from July 15, 2026.
- · The decrease in ownership percentage is solely due to an increase in outstanding shares, not a sale of shares by the Reporting Persons.
- · Diyong Xu, an employee of OrbiMed Advisors, serves on Q32 Bio's board and is subject to a lock-up agreement that requires transfer of any equity compensation to OrbiMed Advisors and GP.
- · The lock-up agreement restricts OPI VII, Genesis, and Xu from selling or hedging shares for 45 trading days from the date of the final prospectus (July 15, 2026).
20-07-2026
BNDES Participacoes S.A. (BNDESPAR) and its sole shareholder BNDES filed Amendment No. 4 to their Schedule 13D, reporting a decrease in their aggregate beneficial ownership of Petrobras preferred shares from 916,700,003 to 865,743,903 shares, representing 15.90% of the class. The reduction resulted from open market sales. Despite the decrease, BNDESPAR directly owns 730,495,645 preferred shares (13.41%), and BNDES directly owns 135,248,258 preferred shares; however, both entities remain prohibited from voting these shares under a 2014 Brazilian Securities Commission order.
- · The decrease was due to open market sales by the Reporting Persons.
- · BNDES and BNDESPAR are prohibited from voting their preferred shares pursuant to a December 2, 2014 decision by the Brazilian Securities Commission (CVM).
- · Preferred shares are not convertible into common shares.
- · Holders of at least 10% of total capital stock have the right to appoint/dismiss one board member and separately appoint one member to the fiscal council.
- · No transactions in preferred shares were effected by any Reporting Person in the 60 days prior to the filing date other than those described.
20-07-2026
Principal Accounting Officer Lally Robert B sold 1,671 Common Stock at $5.50 (~$9.19K). Lally Robert B holds 55,582 shares after the transaction.
- · Principal Accounting Officer Lally Robert B sold 1,671 Common Stock at $5.50 (~$9.19K)
- · Principal Accounting Officer Lally Robert B sold 1,525 Common Stock at $5.34 (~$8.14K)
20-07-2026
EVP/Chief Risk Officer Tomasello Vickie disposed to the issuer 9,070 Common Stock.
- · EVP/Chief Risk Officer Tomasello Vickie disposed to the issuer 9,070 Common Stock
- · EVP/Chief Risk Officer Tomasello Vickie disposed to the issuer 1,138.07 Common Stock
- · EVP/Chief Risk Officer Tomasello Vickie disposed to the issuer 12,966 Restricted Stock Units
20-07-2026
Director Patafio Frank P. disposed to the issuer 267,362 Common Stock.
- · Director Patafio Frank P. disposed to the issuer 267,362 Common Stock
- · Director Patafio Frank P. disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Director Chapman Gil disposed to the issuer 48,005 Common Stock. 4 transactions reported in total.
- · Director Chapman Gil disposed to the issuer 48,005 Common Stock
- · Director Chapman Gil disposed to the issuer 6,763 Common Stock
- · Director Chapman Gil disposed to the issuer 7,651 Common Stock
- · Director Chapman Gil disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Director Harrison Timothy C disposed to the issuer 82,313 Common Stock.
- · Director Harrison Timothy C disposed to the issuer 82,313 Common Stock
- · Director Harrison Timothy C disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
EVP Fasanella David disposed to the issuer 46,019 Common Stock. 5 transactions reported in total.
- · EVP Fasanella David disposed to the issuer 46,019 Common Stock
- · EVP Fasanella David disposed to the issuer 11,500 Common Stock
- · EVP Fasanella David disposed to the issuer 9,611.95 Common Stock
- · EVP Fasanella David disposed to the issuer 2,382.67 Common Stock
- · EVP Fasanella David disposed to the issuer 15,066 Restricted Stock Units
20-07-2026
Director CATINO ANNETTE disposed to the issuer 229,988 Common Stock. 4 transactions reported in total.
- · Director CATINO ANNETTE disposed to the issuer 229,988 Common Stock
- · Director CATINO ANNETTE disposed to the issuer 37,460 Common Stock
- · Director CATINO ANNETTE disposed to the issuer 21,000 Common Stock
- · Director CATINO ANNETTE disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Director Stahlin Paul disposed to the issuer 54,354 Common Stock.
- · Director Stahlin Paul disposed to the issuer 54,354 Common Stock
- · Director Stahlin Paul disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Director Connors John P Jr disposed to the issuer 168,569 Common Stock. 5 transactions reported in total.
- · Director Connors John P Jr disposed to the issuer 168,569 Common Stock
- · Director Connors John P Jr disposed to the issuer 33,181 Common Stock
- · Director Connors John P Jr disposed to the issuer 7,041 Common Stock
- · Director Connors John P Jr disposed to the issuer 841 Common Stock
- · Director Connors John P Jr disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Chairman, President & CEO Klein Steven M disposed to the issuer 464,261 Common Stock. 4 transactions reported in total.
- · Chairman, President & CEO Klein Steven M disposed to the issuer 464,261 Common Stock
- · Chairman, President & CEO Klein Steven M disposed to the issuer 66,997.09 Common Stock
- · Chairman, President & CEO Klein Steven M disposed to the issuer 59,118.88 Common Stock
- · Chairman, President & CEO Klein Steven M disposed to the issuer 40,000 Stock Options
20-07-2026
EVP & PAO Jacobs William R. disposed to the issuer 64,947 Common Stock. 4 transactions reported in total.
- · EVP & PAO Jacobs William R. disposed to the issuer 64,947 Common Stock
- · EVP & PAO Jacobs William R. disposed to the issuer 38,613.64 Common Stock
- · EVP & PAO Jacobs William R. disposed to the issuer 12,949.11 Common Stock
- · EVP & PAO Jacobs William R. disposed to the issuer 15,888 Restricted Stock Units
20-07-2026
Director Kulkarni Rachana A disposed to the issuer 18,688 Common Stock.
- · Director Kulkarni Rachana A disposed to the issuer 18,688 Common Stock
- · Director Kulkarni Rachana A disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
Director Kessler Karen J. disposed to the issuer 64,854 Common Stock.
- · Director Kessler Karen J. disposed to the issuer 64,854 Common Stock
- · Director Kessler Karen J. disposed to the issuer 3,500 Common Stock
- · Director Kessler Karen J. disposed to the issuer 4,383 Restricted Stock Units
20-07-2026
EVP Lefkowitz Robin disposed to the issuer 23,534 Common Stock. 5 transactions reported in total.
- · EVP Lefkowitz Robin disposed to the issuer 23,534 Common Stock
- · EVP Lefkowitz Robin disposed to the issuer 26,135.8 Common Stock
- · EVP Lefkowitz Robin disposed to the issuer 38,388.46 Common Stock
- · EVP Lefkowitz Robin disposed to the issuer 13,879 Restricted Stock Units
- · EVP Lefkowitz Robin disposed to the issuer 40,000 Stock Options
20-07-2026
Chief Scientific Officer Violette Shelia M. was awarded 37,500 Common Stock. Violette Shelia M. holds 130,569 shares after the transaction.
- · Chief Scientific Officer Violette Shelia M. was awarded 37,500 Common Stock
20-07-2026
Goldenwise Capital Group Ltd disclosed a 6.9% beneficial stake in Phunware, Inc. via a Schedule 13D/A filed July 20, 2026. The fund publicly criticized the Board's governance under Chairman Elliot Han, citing prolonged operating losses, shareholder dilution, and a market cap decline from ~$120M raised to ~$40M. Goldenwise has proposed four director candidates and warned it may pursue a proxy contest if the Board does not engage in meaningful governance reforms.
- · Goldenwise holds short put and call option positions in Phunware, including 492 short put options at $2.50 expiring July 2026 and 4,896 short call options at $2.50 expiring July 2026.
- · The fund sent more than 10 emails to Chairman Elliot Han over three months with no reply.
- · Goldenwise proposed four director candidates: Shawn Kravetz, Richard Ding, Mona Zhang, and Steve Han.
- · The Board has not committed to any timetable for governance reforms and has threatened legal action if the open letter is published.
- · Phunware's operating business has consistently lost ~$15M per year on ~$3M revenue since 2024.
21-07-2026
VisionWave Holdings, Inc. entered into a securities purchase agreement on July 20, 2026, to issue up to $15,000,000 in convertible debentures and warrants to accredited investors in a private placement. The first closing of $10,000,000 occurred on or about July 21, 2026, with a second closing of $5,000,000 contingent on SEC effectiveness of a registration statement. The company also issued warrants exercisable for 1,800,000 common shares and agreed to provide registration rights, while the transaction is subject to Nasdaq's exchange cap of 5,513,655 shares unless stockholder approval is obtained.
- · The securities are being sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- · The purchase price for the debentures is 85% of the principal amount, implying an immediate discount for investors.
- · The company must obtain stockholder approval or a legal opinion to issue shares exceeding the exchange cap of 5,513,655 shares.
- · The second closing of $5,000,000 is contingent on the SEC declaring the registration statement effective.
- · The company's subsidiaries are required to enter into a global guaranty agreement in favor of the buyers.
21-07-2026
Innate Pharma S.A. filed a Form 6-K with the SEC on July 21, 2026, attaching a press release of the same date. The filing incorporates the press release by reference into the company's existing registration statements. No specific financial results, material events, or performance metrics are disclosed in the 6-K cover or signature pages.
- · The press release (Exhibit 99.1) is incorporated by reference into Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031).
- · The filing is a routine foreign issuer report under Rule 13a-16 or 15d-16.
21-07-2026
Gerdau S.A. filed a Form 6-K with the SEC on July 20, 2026, announcing the closing of an acquisition of an equity stake. The filing provides no financial details or performance metrics, only confirming the transaction's completion.
- · The filing is dated July 20, 2026, and references Commission File Number 1-14878.
- · The registrant's address is Av. Dra. Ruth Cardoso, 8,501 – 8° andar, São Paulo, Brazil.
- · The filing indicates Gerdau files annual reports under Form 20-F.
21-07-2026
ING Groep N.V. filed a Form 6-K with the SEC on July 21, 2026, attaching a press release of the same date. The filing is a routine foreign issuer report and contains no financial results or material corporate events.
- · The press release is attached as Exhibit 99.1 but its content is not included in the filing.
21-07-2026
América Móvil, through its subsidiary América Móvil Perú S.A.C., has entered into a share purchase agreement to acquire 100% of WOW Tel S.A.C. ("WOW") from Liberty Latin America Ltd. and Narvik Capital Partners PTE. Ltd. WOW provides fixed fiber-optic telecommunications services in Peru, primarily outside Lima. The transaction is subject to customary closing conditions, including regulatory approval from INDECOPI.
- · The acquisition target, WOW, focuses on fixed telecommunication services via fiber-optic connectivity in regions of Peru primarily outside Lima.
- · The transaction is subject to regulatory approval by INDECOPI (National Institute for the Defense of Competition and Protection of Intellectual Property).
21-07-2026
United Microelectronics Corporation (UMC) filed a Form 6-K with the SEC on July 21, 2026, as a routine foreign issuer report. The filing contains no financial results, material events, or operational updates, and appears to be a procedural submission.
21-07-2026
Alterity Therapeutics Ltd filed a Form 6-K with the SEC on July 21, 2026, announcing its participation in the BTIG Biotechnology Conference. The filing is a routine foreign issuer report and does not contain any financial results or material operational updates.
- · The filing incorporates by reference several existing registration statements on Form S-8 and Form F-3.
- · The company is a development stage enterprise.
21-07-2026
Studio City International Holdings Ltd announced the completion of a partial redemption of its US$500,000,000 6.500% Senior Notes due 2028 via a subsidiary. The filing provides no financial performance data or period-over-period comparisons, only a routine debt management update.
- · The partial redemption was completed on July 21, 2026.
- · The announcement was made by subsidiary Studio City Finance Limited.
- · The filing is a Form 6-K under SEC Rule 13a-16 or 15d-16.
Get daily alerts with 10 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →July 21, 2026
S&P 500 Technology Sector SEC Filings — July 21, 2026
S&P 500 Technology Sector SEC Filings
July 21, 2026
US Merger & Acquisition SEC Filings — July 21, 2026
US Merger & Acquisition SEC Filings
July 21, 2026
US Corporate Board Director Changes SEC Filings — July 21, 2026
US Corporate Board Director Changes SEC Filings
July 21, 2026
US Executive Officer Management Changes SEC — July 21, 2026
US Executive Officer Management Changes SEC